Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 2/2022

03.02.2022 | Macrovascular Complications in Diabetes (R SHAH, Section Editor)

Metabolomics of Type 1 and Type 2 Diabetes: Insights into Risk Prediction and Mechanisms

verfasst von: Daniel Gonzalez Izundegui, Matthew Nayor

Erschienen in: Current Diabetes Reports | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Metabolomics enables rapid interrogation of widespread metabolic processes making it well suited for studying diabetes. Here, we review the current status of metabolomic investigation in diabetes, highlighting its applications for improving risk prediction and mechanistic understanding.

Recent findings

Findings of metabolite associations with type 2 diabetes risk have confirmed experimental observations (e.g., branched-chain amino acids) and also pinpointed novel pathways of diabetes risk (e.g., dimethylguanidino valeric acid). In type 1 diabetes, abnormal metabolite patterns are observed prior to the development of autoantibodies and hyperglycemia. Diabetes complications display specific metabolite signatures that are distinct from the metabolic derangements of diabetes and differ across vascular beds. Lastly, metabolites respond acutely to pharmacologic treatment, providing opportunities to understand inter-individual treatment responses.

Summary

Metabolomic studies have elucidated biological mechanisms underlying diabetes development, complications, and therapeutic response. While not yet ready for clinical translation, metabolomics is a powerful and promising precision medicine tool.
Literatur
1.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.PubMedCrossRef
2.
Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66(2):241–55.PubMedCrossRef
3.
Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311–26.PubMedPubMedCentralCrossRef
4.
Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125(18):2222–31.PubMedPubMedCentralCrossRef
5.
Cheng S, Shah SH, Corwin EJ, Fiehn O, Fitzgerald RL, Gerszten RE, et al. Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American Heart Association. Circ Cardiovasc Genet. 2017;10(2):e000032.
6.
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53.PubMedPubMedCentralCrossRef
7.
Walford GA, Ma Y, Clish C, Florez JC, Wang TJ, Gerszten RE, et al. Metabolite profiles of diabetes incidence and intervention response in the diabetes prevention program. Diabetes. 2016;65(5):1424–33.PubMedPubMedCentralCrossRef
8.
Yamakado M, Nagao K, Imaizumi A, Tani M, Toda A, Tanaka T, et al. Plasma free amino acid profiles predict four-year risk of developing diabetes, metabolic syndrome, dyslipidemia, and hypertension in Japanese population. Sci Rep. 2015;5:11918.PubMedPubMedCentralCrossRef
9.
Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost HG, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639–48.PubMedPubMedCentralCrossRef
10.
Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2013;62(5):1730–7.PubMedPubMedCentralCrossRef
11.
Wurtz P, Tiainen M, Makinen VP, Kangas AJ, Soininen P, Saltevo J, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care. 2012;35(8):1749–56.PubMedPubMedCentralCrossRef
12.
Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3(2):207–14.PubMedCrossRef
13.
Magnusson M, Lewis GD, Ericson U, Orho-Melander M, Hedblad B, Engstrom G, et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J. 2013;34(26):1982–9.PubMedCrossRef
14.
White PJ, Newgard CB. Branched-chain amino acids in disease. Science. 2019;363(6427):582–3.PubMedCrossRef
15.
Zhao H, Zhang F, Sun D, Wang X, Zhang X, Zhang J, et al. Branched-chain amino acids exacerbate obesity-related hepatic glucose and lipid metabolic disorders via attenuating Akt2 signaling. Diabetes. 2020;69(6):1164–77.PubMedCrossRef
16.
•• White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metab. 2018;27(6):1281–93 e7. This study demonstrated that branched-chain ketoacid dehydrogenase is an important regulator of the effects of BCAAs on glucose tolerance and elucidated some of the mechanisms responsible for the association of BCAAs and diabetes risk.PubMedPubMedCentralCrossRef
17.
Qureshi W, Santaren ID, Hanley AJ, Watkins SM, Lorenzo C, Wagenknecht LE. Risk of diabetes associated with fatty acids in the de novo lipogenesis pathway is independent of insulin sensitivity and response: the Insulin Resistance Atherosclerosis Study (IRAS). BMJ Open Diabetes Res Care. 2019;7(1):e000691.PubMedPubMedCentralCrossRef
18.
Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin T, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a Mendelian randomisation analysis. PLoS Med. 2016;13(11):e1002179.PubMedPubMedCentralCrossRef
19.
Wopereis S, Rubingh CM, van Erk MJ, Verheij ER, van Vliet T, Cnubben NH, et al. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS One. 2009;4(2):e4525.PubMedPubMedCentralCrossRef
20.
Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7(1):45–56.PubMedCrossRef
21.
•• Robbins JM, Herzig M, Morningstar J, Sarzynski MA, Cruz DE, Wang TJ, et al. Association of dimethylguanidino valeric acid with partial resistance to metabolic health benefits of regular exercise. JAMA Cardiol. 2019;4(7):636–43. A study characterizing the response of the metabolite DMGV to exercise training.PubMedPubMedCentralCrossRef
22.
•• Nayor M, Shah RV, Miller PE, Blodgett JB, Tanguay M, Pico AR, et al. Metabolic architecture of acute exercise response in middle-aged adults in the community. Circulation. 2020;142(20):1905–24. This study described the response of the circulating metabolome to exercise, demonstrating favorable effects on broad metabolic pathways.PubMedPubMedCentralCrossRef
23.
Lee HJ, Jang HB, Kim WH, Park KJ, Kim KY, Park SI, et al. 2-Aminoadipic acid (2-AAA) as a potential biomarker for insulin resistance in childhood obesity. Sci Rep. 2019;9(1):13610.PubMedPubMedCentralCrossRef
24.
•• Li Q, Parikh H, Butterworth MD, Lernmark A, Hagopian W, Rewers M, et al. Longitudinal metabolome-wide signals prior to the appearance of a first islet autoantibody in children participating in the TEDDY study. Diabetes. 2020;69(3):465–76. Another study describing distinct metabolic signatures that can be identified prior to autoantibody formation in type 1 diabetes. Here, the investigators compared different types of autoantibodies.PubMedPubMedCentralCrossRef
25.
•• Curovic VR, Suvitaival T, Mattila I, Ahonen L, Trost K, Theilade S, et al. Circulating metabolites and lipids are associated to diabetic retinopathy in individuals with type 1 diabetes. Diabetes. 2020;69(10):2217–26. A large, prospective study of individuals with type 1 diabetes, demonstrating novel metabolite associations with diabetic retinopathy.PubMedPubMedCentralCrossRef
26.
Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969;281(15):811–6.PubMedCrossRef
27.
Liu X, Zheng Y, Guasch-Ferré M, Ruiz-Canela M, Toledo E, Clish C, et al. High plasma glutamate and low glutamine-to-glutamate ratio are associated with type 2 diabetes: case-cohort study within the PREDIMED trial. Nutr Metab Cardiovasc Dis. 2019;29(10):1040–9.PubMedCrossRef
28.
29.
Guasch-Ferre M, Hruby A, Toledo E, Clish CB, Martinez-Gonzalez MA, Salas-Salvado J, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39(5):833–46.PubMedPubMedCentralCrossRef
30.
Crawford SO, Hoogeveen RC, Brancati FL, Astor BC, Ballantyne CM, Schmidt MI, et al. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. Int J Epidemiol. 2010;39(6):1647–55.PubMedPubMedCentralCrossRef
31.
DiGirolamo M, Newby FD, Lovejoy J. Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J. 1992;6(7):2405–12.PubMedCrossRef
32.
O’Sullivan JF, Morningstar JE, Yang Q, Zheng B, Gao Y, Jeanfavre S, et al. Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. J Clin Invest. 2017;127(12):4394–402.PubMedPubMedCentralCrossRef
33.
Ottosson F, Ericson U, Almgren P, Smith E, Brunkwall L, Hellstrand S, et al. Dimethylguanidino valerate: a lifestyle-related metabolite associated with future coronary artery disease and cardiovascular mortality. J Am Heart Assoc. 2019;8(19):e012846.PubMedPubMedCentralCrossRef
34.
Roberts LD, Bostrom P, O’Sullivan JF, Schinzel RT, Lewis GD, Dejam A, et al. beta-Aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014;19(1):96–108.PubMedPubMedCentralCrossRef
35.
Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123(10):4309–17.PubMedPubMedCentralCrossRef
36.
Aslam M, Aggarwal S, Sharma KK, Galav V, Madhu SV. Postprandial hypertriglyceridemia predicts development of insulin resistance glucose intolerance and type 2 diabetes. PLoS One. 2016;11(1):e0145730.PubMedPubMedCentralCrossRef
37.
Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest. 2011;121(4):1402–11.PubMedPubMedCentralCrossRef
38.
Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009;139(6):1073–81.PubMedPubMedCentralCrossRef
39.
Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.PubMedPubMedCentralCrossRef
40.
Cole LK, Vance JE, Vance DE. Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim Biophys Acta. 2012;1821(5):754–61.PubMedCrossRef
41.
Dutta T, Chai HS, Ward LE, Ghosh A, Persson XM, Ford GC, et al. Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes. 2012;61(5):1004–16.PubMedPubMedCentralCrossRef
42.
•• Lamichhane S, Kemppainen E, Trost K, Siljander H, Hyoty H, Ilonen J, et al. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. Diabetologia. 2019;62(12):2287–97. A comprehensive report of changes in metabolites preceding the development of type 1 diabetes, supporting the hypothesis that more widespread metabolic dysfunction is responsible for type 1 diabetes pathogenesis.PubMedPubMedCentralCrossRef
43.
Lamichhane S, Ahonen L, Dyrlund TS, Kemppainen E, Siljander H, Hyoty H, et al. Dynamics of plasma lipidome in progression to islet autoimmunity and type 1 diabetes - Type 1 Diabetes Prediction and Prevention Study (DIPP). Sci Rep. 2018;8(1):10635.PubMedPubMedCentralCrossRef
44.
Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. 2008;205(13):2975–84.PubMedPubMedCentralCrossRef
45.
Eid S, Sas KM, Abcouwer SF, Feldman EL, Gardner TW, Pennathur S, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62(9):1539–49.PubMedPubMedCentralCrossRef
46.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.PubMedCrossRef
47.
Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, et al. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019;380(23):2215–24.PubMedPubMedCentralCrossRef
48.
49.
Yun JH, Kim JM, Jeon HJ, Oh T, Choi HJ, Kim BJ. Metabolomics profiles associated with diabetic retinopathy in type 2 diabetes patients. PLoS One. 2020;15(10):e0241365.PubMedPubMedCentralCrossRef
50.
Sugai M, Ohta A, Ogata Y, Nakanishi M, Ueno S, Kawata T, et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J. 2007;54(2):303–9.PubMedCrossRef
51.
Malecki MT, Undas A, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow P, Osmenda G, et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care. 2007;30(11):2899–901.PubMedCrossRef
52.
Sumarriva K, Uppal K, Ma C, Herren DJ, Wang Y, Chocron IM, et al. Arginine and carnitine metabolites are altered in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2019;60(8):3119–26.PubMedPubMedCentralCrossRef
53.
54.
•• Welsh P, Rankin N, Li Q, Mark PB, Wurtz P, Ala-Korpela M, et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia. 2018;61(7):1581–91. A substudy of the ADVANCE trial demonstrating associations of baseline amino acid levels with long-term microvascular and macrovascular outcomes.PubMedPubMedCentralCrossRef
55.
Rhee SY, Jung ES, Suh DH, Jeong SJ, Kim K, Chon S, et al. Plasma amino acids and oxylipins as potential multi-biomarkers for predicting diabetic macular edema. Sci Rep. 2021;11(1):9727.PubMedPubMedCentralCrossRef
56.
Zuo J, Lan Y, Hu H, Hou X, Li J, Wang T, et al. Metabolomics-based multidimensional network biomarkers for diabetic retinopathy identification in patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2021;9(1):e001443.
57.
Zhu XR, Yang FY, Lu J, Zhang HR, Sun R, Zhou JB, et al. Plasma metabolomic profiling of proliferative diabetic retinopathy. Nutr Metab (Lond). 2019;16:37.CrossRef
58.
Rhee SY, Jung ES, Park HM, Jeong SJ, Kim K, Chon S, et al. Plasma glutamine and glutamic acid are potential biomarkers for predicting diabetic retinopathy. Metabolomics. 2018;14(7):89.PubMedPubMedCentralCrossRef
59.
Chen L, Cheng CY, Choi H, Ikram MK, Sabanayagam C, Tan GS, et al. Plasma metabonomic profiling of diabetic retinopathy. Diabetes. 2016;65(4):1099–108.PubMedCrossRef
60.
Kwon B, Lee HK, Querfurth HW. Oleate prevents palmitate-induced mitochondrial dysfunction, insulin resistance and inflammatory signaling in neuronal cells. Biochim Biophys Acta. 2014;1843(7):1402–13.PubMedCrossRef
61.
Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634–40.PubMedPubMedCentralCrossRef
62.
Fridman V, Zarini S, Sillau S, Harrison K, Bergman BC, Feldman EL, et al. Altered plasma serine and 1-deoxydihydroceramide profiles are associated with diabetic neuropathy in type 2 diabetes and obesity. J Diabetes Complicat. 2021;35(4):107852.CrossRef
63.
Rumora AE, Guo K, Alakwaa FM, Andersen ST, Reynolds EL, Jorgensen ME, et al. Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes. Ann Clin Transl Neurol. 2021;8(6):1292–307.PubMedPubMedCentralCrossRef
64.
O’Brien PD, Guo K, Eid SA, Rumora AE, Hinder LM, Hayes JM, et al. Integrated lipidomic and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and type 2 diabetes. Dis Model Mech. 2020;13(2):dmm042101.
65.
Freeman OJ, Unwin RD, Dowsey AW, Begley P, Ali S, Hollywood KA, et al. Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy. Diabetes. 2016;65(1):228–38.PubMedCrossRef
66.
Duran AM, Salto LM, Camara J, Basu A, Paquien I, Beeson WL, et al. Effects of omega-3 polyunsaturated fatty-acid supplementation on neuropathic pain symptoms and sphingosine levels in Mexican-Americans with type 2 diabetes. Diabetes Metab Syndr Obes. 2019;12:109–20.PubMedPubMedCentralCrossRef
67.
68.
Roointan A, Gheisari Y, Hudkins KL, Gholaminejad A. Non-invasive metabolic biomarkers for early diagnosis of diabetic nephropathy: meta-analysis of profiling metabolomics studies. Nutr Metab Cardiovasc Dis. 2021;31(8):2253–72.PubMedCrossRef
69.
Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med. 2017;23(6):753–62.PubMedPubMedCentralCrossRef
70.
•• Gordin D, Shah H, Shinjo T, St-Louis R, Qi W, Park K, et al. Characterization of glycolytic enzymes and pyruvate kinase M2 in type 1 and 2 diabetic nephropathy. Diabetes Care. 2019;42(7):1263–73. A translational investigation in plasma and kidney biopsy samples demonstrating that upregulation of glycolytic enzymes is associated with preservation of kidney function in both type 1 and type 2 diabetes.PubMedPubMedCentralCrossRef
71.
Zhang F, Guo R, Cui W, Wang L, Xiao J, Shang J, et al. Untargeted serum metabolomics and tryptophan metabolism profiling in type 2 diabetic patients with diabetic glomerulopathy. Ren Fail. 2021;43(1):980–92.PubMedPubMedCentralCrossRef
72.
Afshinnia F, Rajendiran TM, Wernisch S, Soni T, Jadoon A, Karnovsky A, et al. Lipidomics and biomarker discovery in kidney disease. Semin Nephrol. 2018;38(2):127–41.PubMedPubMedCentralCrossRef
73.
•• Mutter S, Valo E, Aittomaki V, Nybo K, Raivonen L, Thorn LM, et al. Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes. Diabetologia. 2022;65(1):140–9. A prospective study of the association of urinary metabolites with the development of future diabetic nephropathy in >2000 individuals with type 1 diabetes.PubMedCrossRef
74.
Ekstrand AV, Groop PH, Grönhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant. 1998;13(12):3079–83.PubMedCrossRef
75.
Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRef
76.
Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef
77.
Haas AV, McDonnell ME. Pathogenesis of cardiovascular disease in diabetes. Endocrinol Metab Clin N Am. 2018;47(1):51–63.CrossRef
78.
Ottosson F, Smith E, Gallo W, Fernandez C, Melander O. Purine metabolites and carnitine biosynthesis intermediates are biomarkers for incident type 2 diabetes. J Clin Endocrinol Metab. 2019;104(10):4921–30.PubMedPubMedCentralCrossRef
79.
Ottosson F, Smith E, Fernandez C, Melander O. Plasma metabolites associate with all-cause mortality in individuals with type 2 diabetes. Metabolites. 2020;10(8):315.
80.
Ottosson F, Smith E, Melander O, Fernandez C. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. J Clin Endocrinol Metab. 2018;103(8):3060–9.PubMedCrossRef
81.
Contrepois K, Wu S, Moneghetti KJ, Hornburg D, Ahadi S, Tsai MS, et al. Molecular choreography of acute exercise. Cell. 2020;181(5):1112–30. e16PubMedPubMedCentralCrossRef
82.
Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, et al. Metabolite profiles during oral glucose challenge. Diabetes. 2013;62(8):2689–98.PubMedPubMedCentralCrossRef
83.
Morris C, O’Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, et al. Identification of differential responses to an oral glucose tolerance test in healthy adults. PLoS One. 2013;8(8):e72890.PubMedPubMedCentralCrossRef
84.
Fiamoncini J, Rundle M, Gibbons H, Thomas EL, Geillinger-Kastle K, Bunzel D, et al. Plasma metabolome analysis identifies distinct human metabotypes in the postprandial state with different susceptibility to weight loss-mediated metabolic improvements. FASEB J. 2018;32(10):5447–58.PubMedCrossRef
85.
•• Li-Gao R, Hughes DA, van Klinken JB, de Mutsert R, Rosendaal FR, Mook-Kanamori DO, et al. Genetic studies of metabolomics change after a liquid meal illuminate novel pathways for glucose and lipid metabolism. Diabetes. 2021;70(12):2932–46. Genetic analyses of the individual responses to a mixed meal tolerance test, identifying genetic variants associated with the post-meal response to lipid handling.PubMedCrossRef
86.
Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012;55(2):321–30.PubMedCrossRef
87.
•• Chen ZZ, Liu J, Morningstar J, Heckman-Stoddard BM, Lee CG, Dagogo-Jack S, et al. Metabolite profiles of incident diabetes and heterogeneity of treatment effect in the Diabetes Prevention Program. Diabetes. 2019;68(12):2337–49. A report from the Diabetes Prevention Program illustrating how heterogeneity in metabolic profiles may predict response to pharmacologic versus lifestyle treatments.PubMedPubMedCentralCrossRef
88.
Shantavasinkul PC, Muehlbauer MJ, Bain JR, Ilkayeva OR, Craig DM, Newgard CB, et al. Improvement in insulin resistance after gastric bypass surgery is correlated with a decline in plasma 2-hydroxybutyric acid. Surg Obes Relat Dis. 2018;14(8):1126–32.PubMedPubMedCentralCrossRef
89.
Laferrere B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011;3(80):80re2.PubMedPubMedCentralCrossRef
90.
Chung WK, Erion K, Florez JC, Hattersley AT, Hivert MF, Lee CG, et al. Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(9):1671–93.PubMedPubMedCentralCrossRef
91.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–74.PubMedPubMedCentralCrossRef
92.
den Ouden H, Pellis L, Rutten G, Geerars-van Vonderen IK, Rubingh CM, van Ommen B, et al. Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. Metabolomics. 2016;12:27.CrossRef
93.
Dahabiyeh LA, Mujammami M, Arafat T, Benabdelkamel H, Alfadda AA, Abdel Rahman AM. A metabolic pattern in healthy subjects given a single dose of metformin: a metabolomics approach. Front Pharmacol. 2021;12:705932.PubMedPubMedCentralCrossRef
94.
Kappel BA, Lehrke M, Schutt K, Artati A, Adamski J, Lebherz C, et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation. 2017;136(10):969–72.PubMedCrossRef
95.
Mulder S, Hammarstedt A, Nagaraj SB, Nair V, Ju W, Hedberg J, et al. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes Obes Metab. 2020;22(7):1157–66.PubMedPubMedCentralCrossRef
96.
Packer M. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovasc Diabetol. 2020;19(1):62.PubMedPubMedCentralCrossRef
97.
Dutta T, Kudva YC, Persson XM, Schenck LA, Ford GC, Singh RJ, et al. Impact of long-term poor and good glycemic control on metabolomics alterations in type 1 diabetic people. J Clin Endocrinol Metab. 2016;101(3):1023–33.PubMedPubMedCentralCrossRef
98.
Knebel B, Strassburger K, Szendroedi J, Kotzka J, Scheer M, Nowotny B, et al. Specific metabolic profiles and their relationship to insulin resistance in recent-onset type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2016;101(5):2130–40.PubMedCrossRef
99.
100.
Nayor M, Shah SH, Murthy V, Shah RV. Molecular aspects of lifestyle and environmental effects in patients with diabetes: JACC Focus Seminar. J Am Coll Cardiol. 2021;78(5):481–95.PubMedCrossRef
Metadaten
Titel
Metabolomics of Type 1 and Type 2 Diabetes: Insights into Risk Prediction and Mechanisms
verfasst von
Daniel Gonzalez Izundegui
Matthew Nayor
Publikationsdatum
03.02.2022
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 2/2022
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-022-01449-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise